IGF1 and myotonic dystrophy type 1: In one published clinical trial (NCT00233519) involving 15 participants, SomatoKine (Iplex), a combination of IGF-1 and IGF-1 binding protein-3, was administered to patients with myotonic dystrophy type 1, indicating that SomatoKine could enhance lean body muscle mass and metabolism without significantly improving muscle strength or function [442].